Zevra Therapeutics Past Earnings Performance
Past criteria checks 0/6
Zevra Therapeutics's earnings have been declining at an average annual rate of -4.3%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 17.8% per year.
Key information
-4.3%
Earnings growth rate
73.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 17.8% |
| Return on equity | -74.4% |
| Net Margin | -167.7% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Zevra Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 27 | -46 | 35 | 39 |
| 30 Sep 23 | 17 | -40 | 25 | 34 |
| 30 Jun 23 | 17 | -32 | 23 | 27 |
| 31 Mar 23 | 9 | -51 | 20 | 25 |
| 31 Dec 22 | 10 | -27 | 16 | 19 |
| 30 Sep 22 | 11 | -35 | 13 | 16 |
| 30 Jun 22 | 10 | -30 | 11 | 12 |
| 31 Mar 22 | 20 | -17 | 10 | 10 |
| 31 Dec 21 | 29 | -63 | 9 | 10 |
| 30 Sep 21 | 28 | -65 | 9 | 10 |
| 30 Jun 21 | 28 | -66 | 9 | 9 |
| 31 Mar 21 | 23 | -55 | 8 | 8 |
| 31 Dec 20 | 13 | -13 | 8 | 8 |
| 30 Sep 20 | 12 | -14 | 7 | 8 |
| 30 Jun 20 | 22 | -8 | 10 | 10 |
| 31 Mar 20 | 15 | -18 | 11 | 12 |
| 31 Dec 19 | 13 | -25 | 11 | 19 |
| 30 Sep 19 | 11 | -24 | 13 | 23 |
| 30 Jun 19 | 0 | -42 | 12 | 32 |
| 31 Mar 19 | 0 | -43 | 13 | 38 |
| 31 Dec 18 | 0 | -56 | 13 | 41 |
| 30 Sep 18 | 0 | -62 | 13 | 41 |
| 30 Jun 18 | 0 | -57 | 13 | 33 |
| 31 Mar 18 | 0 | -53 | 13 | 28 |
| 31 Dec 17 | 0 | -43 | 13 | 20 |
| 30 Sep 17 | 0 | -43 | 13 | 23 |
| 30 Jun 17 | 0 | -45 | 13 | 21 |
| 31 Mar 17 | 0 | -30 | 14 | 21 |
| 31 Dec 16 | 0 | -17 | 14 | 20 |
| 30 Sep 16 | 0 | -16 | 14 | 17 |
| 30 Jun 16 | 0 | -13 | 13 | 17 |
| 31 Mar 16 | 0 | -52 | 12 | 15 |
| 31 Dec 15 | 0 | -55 | 9 | 14 |
| 30 Sep 15 | 0 | -57 | 8 | 15 |
| 30 Jun 15 | 0 | -55 | 7 | 14 |
| 31 Mar 15 | 0 | -29 | 5 | 13 |
| 31 Dec 14 | 0 | -24 | 5 | 12 |
| 30 Sep 14 | 0 | -14 | 3 | 7 |
Quality Earnings: 1GDA is currently unprofitable.
Growing Profit Margin: 1GDA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1GDA is unprofitable, and losses have increased over the past 5 years at a rate of 4.3% per year.
Accelerating Growth: Unable to compare 1GDA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 1GDA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.8%).
Return on Equity
High ROE: 1GDA has a negative Return on Equity (-74.44%), as it is currently unprofitable.